Columns

Blocking the expression of mutated huntingtin — the protein involved in Huntington’s disease — by directly targeting the faulty gene may be a way of stopping disease progression in patients, according to results of an early study. The study was published in the journal Nucleic Acids Research, under the title “CTG…

NUI Galway researcher and Professor Robert Lahue has been awarded a newly launched grant to investigate potential treatments for Huntington’s disease. The grant is a joint initiative of the Biotechnology and Biological Sciences Research Council UK (BBSRC) and the Science Foundation Ireland (SFI). The grant will provide nearly 700,000…

Enhancing a cell’s quality control mechanism to get rid of the faulty proteins that are a hallmark of Huntington’s disease may help prevent patients’ motor and cognitive loss, a study suggests. The researchers’ discovery of how the quality control mechanism fails may pave the way toward the development of novel therapies…

Patients with Huntington’s disease with low levels of perceived psychological distress may have weaker social cognitive skills, according to a new study. However, researchers think that this association (self-reporting of psychological distress and social cognitive test performance) may be due to apathy and/or impaired insight, which are common in this disease.

The European Union is inviting researchers in 20 countries to work together on projects focusing on Huntington’s disease (HD) and other degenerative diseases. The agency sponsoring the effort, the Joint Programme — Neurodegenerative Disease Research (JPND), said in a press release that neurodegenerative conditions have become a global health epidemic, with heavy economic…

Mitochondrial abnormalities may not contribute to the degeneration of neurons in the striatum in patients with Huntington’s disease, according to a study that provides evidence contradicting several earlier findings. The study explored mitochondrial processes in a mouse model of Huntington’s disease and found that mitochondria from the striatum — the…

A patent application for Vybion’s potential gene therapy for Huntington’s disease (HD) and other neurodegenerative conditions has been granted Track One status by the U.S. Patent and Trademark Office (USPTO). Patent applications are ordinarily reviewed in the order of their filing date, with the process taking about three…

Two large surveys that explore the views of adult and juvenile Huntington’s disease patients and their caregivers on symptoms and treatments may help direct research efforts toward issues that matter most to those affected. Interestingly, the symptom-focused survey revealed large differences in how patients and caregivers perceive the frequency and…

A subtype of brain cells called astrocytes could be contributing to the death of neurons in neurodegenerative diseases such as Huntington’s disease (HD), according to a new study published in the leading scientific journal Nature. This new finding presented in a report titled “Neurotoxic reactive astrocytes are induced by activated microglia” is important because it provides opportunities for scientists to develop new treatment approaches to treat Huntington’s and other neurodegenerative diseases.

A protein called Nrf2 can help maintain healthy levels of proteins associated with neurodegenerative diseases, including Huntington’s disease, thereby protecting neurons from death, according to new research. Results of the study, “Nrf2 Mitigates LRRK2- And α-synuclein–induced Neurodegeneration By Modulating Proteostasis,” were published in the journal PNAS. Neurodegenerative disorders…